Live feed08:00:00·36dPRReleasevia QuantisnowSolid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular DystrophyByQuantisnow·Wall Street's wire, on your screen.SLDB· Solid Biosciences Inc.Health Care
